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Abstract
Purpose—The lack of an ongoing surveillance system for hemoglobinopathies in the United 
States impedes the ability of public health organizations to identify individuals with these 
conditions, monitor their health-care utilization and clinical outcomes, and understand the effect 
these conditions have on the health-care system. This article describes the results of a pilot 
program that supported the development of the infrastructure and data collection methods for a 
state-based surveillance system for selected hemoglobinopathies.
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Methods—The system was designed to identify and gather information on all people living with 
a hemoglobinopathy diagnosis (sickle cell diseases or thalassemias) in the participating states 
during 2004–2008. Novel, three-level case definitions were developed, and multiple data sets were 
used to collect information.
Results—In total, 31,144 individuals who had a hemoglobinopathy diagnosis during the study 
period were identified in California; 39,633 in Florida; 20,815 in Georgia; 12,680 in Michigan; 
34,853 in New York, and 8,696 in North Carolina.
Conclusion—This approach provides a possible model for the development of state-based 
hemoglobinopathy surveillance systems.
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INTRODUCTION
The hemoglobinopathies are a group of inherited blood disorders caused by mutations in the 
globin genes and include sickle cell diseases (SCDs) and the α- and β-thalassemias. Despite 
the public health burden these disorders pose, the only existing universal hemoglobinopathy 
screening and reporting activities in the United States are the state-based newborn screening 
(NBS) programs; evaluation data from various state NBS programs have been voluntarily 
submitted to a national database since 1989.1 Screening for SCDs has been included on the 
recommended uniform NBS panel in all 50 states since 2006, but α- and β-thalassemia 
screening and reporting of results for newborns is currently performed in only a few 
states.2,3 However, many people at risk for a hemoglobinopathy who reside in the United 
States were born either before the implementation of NBS in their state or in a country 
without NBS. For these reasons, the true prevalence and burden of hemoglobinopathies in 
the United States is unknown.
A comprehensive understanding of the impact of hemoglobinopathies in the United States is 
important to public health practitioners, researchers, health insurers, and policy makers. 
Over the past several years, multiple stakeholders have identified the need for improved data 
collection as a priority. In 2007, the American Society of Pediatric Hematology/Oncology 
Sickle Cell Summit identified population-based surveillance to measure outcomes as one of 
five major areas of opportunity for improvement in understanding and treating SCDs.4 In 
2008, the National Institutes of Health convened the Consensus Conference on Hydroxyurea 
Treatment for Sickle Cell Disease, which said that “a surveillance system is needed for 
patients with sickle cell disease . . . it should contain demographic, laboratory, clinical, 
treatment, and outcome information.”5
As a result of these meetings, the National Heart, Lung, and Blood Institute/National 
Institutes of Health and the Division of Blood Disorders at the Centers for Disease Control 
and Prevention collaborated to develop a state-based surveillance system for SCD and 
thalassemia. The purpose of this article is to describe the efforts of the participating states 
and federal agencies to establish the infrastructure and data collection methods for the 
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system and to provide data on the number and characteristics of individuals with a 
hemoglobinopathy diagnosis identified in each of the states.
MATERIALS AND METHODS
Population
The Registry and Surveillance System for Hemoglobinopathies (RuSH) began with 
implementation in six states (California, Florida, Georgia, Michigan, North Carolina, and 
Pennsylvania) in February 2010; a seventh state (New York) was added in September of that 
year. In 2008, these seven states represented ~38% of the total population, 42% of the black 
population, 54% of the Asian population, and 49% of the Hispanic population in the United 
States (http://www.census.gov). Hemoglobinopathies are most common among members of 
these races (black and Asian) and ethnicity (Hispanic). The goal of RuSH was to identify 
and collect data on all people with a hemoglobinopathy diagnosis living in these states 
during 2004–2008.
Work groups
Three work groups were convened to establish the parameters and functional components of 
RuSH. The Data Collection and Harmonization Work Group assisted in identifying data 
sources for case ascertainment, provided guidance on the design and development of data 
collection tools and the data system, and made recommendations for data linkage, 
harmonization, security, quality assurance, and statistical analysis issues. The Surveillance 
Design Work Group provided guidance on the interpretation and use of clinical and 
laboratory information, developed case definitions, and identified and refined the clinical 
variables to be collected and analyzed in the surveillance system. The Community 
Partnerships and Health Education Work Group provided guidance on methods for 
community outreach, education, and communication about RuSH and determined 
implications for sharing of data collected by the program. During the first year of the 
project, each of the work groups met at least one time each month by phone, as well as for a 
1-day, face-to-face meeting. They were convened as necessary for the remainder of the 
project period. The work groups consisted of representatives from the seven RuSH states, 
additional subject matter experts, and federal agency employees.
Case definitions
The Surveillance Design Work Group established three-level case definitions for SCD and 
for the thalassemias, based on laboratory results and International Classification of Diseases, 
Clinical Modification, Ninth Revision and Tenth Revision (ICD-9-CM and ICD-10-CM, 
respectively) codes (Table 1). The levels were constructed to be indicative of the predicted 
reliability of the hemoglobinopathy diagnosis, with level 1 being the most reliable and level 
3 the least, and they allowed for future analysis of subgroups of the study population, based 
on those levels of diagnostic certainty. The hemoglobinopathy-associated procedures, 
complications, and treatments that were included in the case definitions were based on a 
review of the literature, as well as on the professional opinions of the Surveillance Design 
Work Group members. The purpose of these items was to provide more certainty about the 
diagnoses than the diagnostic ICD codes alone would have provided.
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All seven states had mandated universal NBS programs for SCD, with start dates ranging 
from 4 January 1975 in New York to 10 January 1998 in Georgia.3 However, only 
California mandated NBS and standardized reporting for α- and β-thalassemia disorders. 
Therefore, because individuals may have been born before NBS started in their state or in a 
country without hemoglobinopathy NBS, it was necessary to use data from additional 
sources to identify all people with a hemoglobinopathy diagnosis. NBS records, hospital 
discharge data, emergency room records, death records, clinical records, and state Medicaid 
claims were used for both case identification and as sources of demographic, medical, and 
health-care utilization data. Birth and immunization records were used only as sources for 
demographic, maternal, and vaccination data for patients identified with a 
hemoglobinopathy diagnosis; they did not provide any hemoglobinopathy-specific 
information. Additional data sources, such as the Pregnancy Risk Assessment Monitoring 
System, cancer registries, birth defect registries, blood bank data sets, and Medicare, were 
initially considered for inclusion in the project. However, it was determined that either (i) 
the additional variables that could be collected from these data sources did not fit the 
objectives of RuSH, or (ii) it was not possible for the states to access individual-level data 
with identifying variables from the data source. Each state used a unique combination of 
data sources for the project, depending on the data sets to which they were able to obtain 
access.
Data collection/linkage/deduplication
The variety of available data sources and the potential linking variables (name, social 
security number, date of birth, sex, mother's name, phone number, county, partial zip code, 
address, and/or diagnosis) available in each data source necessitated a unique approach to 
data collection, linkage, and deduplication for each state. In general, individuals with a 
hemoglobinopathy diagnosis were identified by a positive laboratory result for SCD or 
thalassemia or ICD-9-CM or ICD-10-CM code in each data set. Next, data sets were 
matched and merged, one pair at a time, using a probabilistic algorithm that assigned 
different weights to the available linking variables. Elements of the case definitions were 
identified both within and across data sources. For example, the requirement that a case have 
two or more health-care encounters with relevant ICD-9-CM or ICD-10-CM codes could be 
met using hospital discharge records alone or by combining a hospital discharge record with 
a Medicaid outpatient record. Deduplication of cases also took place both within and across 
the linked data sources; the goal was for each state to create one final data set that included a 
single record with information on all variables for each identified individual. Using these 
methods, individuals with a hemoglobinopathy diagnosis were identified, their population 
profiles were established, and additional data sources (such as birth records) were used to 
augment their clinical information.
RESULTS
The number of unique individuals who fit the RuSH case definition, by definition level and 
state, are provided for SCD (Table 2) and thalassemia (Table 3) for six of the RuSH states 
(data from the seventh state were not available at the time of publication). They are further 
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subdivided by data source in Supplementary Tables S1 and S2 online. The percentage of 
cases contributed by each data source varied within each state by case definition level and 
across states. For example, in California, the state Medicaid database (MediCal) contained 
56.1% of the individuals identified as SCD level 1, 80.2% of those SCD level 2, and 78.5% 
of those SCD level 3. However, in North Carolina the state Medicaid database contained 
44.7% of the individuals identified as SCD level 1, 31.9% of those SCD level 2, and 26.3% 
of those SCD level 3.
The sex, ethnicity, race, and mean age of the individuals identified with SCD, by state and 
case definition level, are provided in Supplementary Table S3 online. The percentage of 
females was higher in level 2 as compared with level 1, and then higher again in level 3 for 
each state. Overall, the majority of individuals identified with SCDs were black or African 
American; however, this percentage was higher in level 1 as compared with level 3 in the 
data set from each state. The mean age was lowest for the individuals identified as level 1. 
The absolute number of individuals identified as level 3 was greater than the number of 
individuals identified as level 1 or level 2 combined, in all states except for North Carolina.
The majority of individuals identified with thalassemia in California, Georgia, and Michigan 
were Asian, whereas the majority in Florida, New York, and North Carolina were black or 
African American (see Supplementary Table S4 online). As with SCD, the mean age was 
lowest for level 1, and the number of individuals identified as level 3 was higher than levels 
1 and 2 combined in all states.
As a result of the RuSH case definition specifications, geno-type information was available 
only for the individuals identified as level 1 (Table 4). The percentage of individuals with 
hemoglobin S/S or hemoglobin S/β0 thalassemia ranged from 55.3% in Michigan to 66.2% 
in Georgia. New York had the highest percentage of hemoglobin S/C (34.7%), and 
Michigan had the highest percentage of hemoglobin S/β+ thalassemia (11.2%). Data are also 
presented for thalassemia.
DISCUSSION
The Registry and Surveillance System for Hemoglobinopathies used novel case definitions 
to identify individuals with hemoglobinopathies across multiple data sources and collected 
information on their demographics, clinical characteristics, and health-care utilization. Each 
of the participating states developed an estimate of the number of people living with these 
conditions and a profile of these populations. The project also provided each state with a 
better understanding of the strengths and limitations of how existing data sources could be 
leveraged to conduct surveillance of hemoglobinopathies.
One of the strengths of the RuSH project was the inclusion of a three-level case definition. 
The individuals identified as level 1 had the most evidence of truly having a hemoglobin-
opathy, whereas the individuals identified as level 3 had the least amount of evidence. The 
utility of this multitiered case definition was that it enabled subsets of the data to be 
analyzed based on the degree of confidence we had for each level to indicate accurate 
hemoglobinopathy diagnoses. For example, we were able to compare the results of our data 
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collection with previously published estimates from Brousseau et al.6 and Hassell7 
(Supplementary Table S5 online). When making this comparison, we chose to include only 
the individuals identified as SCD level 1 and level 2 because of our uncertainty about the 
accuracy of SCD level 3 diagnoses. Brousseau et al. used census data adjusted for mortality 
rates by sickle cell type to report the number of blacks and Hispanics with SCD in each 
state. Hassell also compiled population estimates for each state by using information from a 
variety of data sources, again adjusted for early SCD mortality. Compared with the data 
from Brousseau et al., the RuSH numbers are lower for California, Florida, Michigan, and 
New York and higher for Georgia and North Carolina. The RuSH numbers for Florida and 
New York fall within the range reported in the article by Hassell; California, Georgia, and 
North Carolina are higher than the range reported by Hassell; Michigan's numbers are lower 
than the range. Because Hassell's and Brousseau et al.'s estimates of the number of 
individuals living with SCD in the seven RuSH states are the only ones currently available, 
it is worthwhile to note the similarities and differences among the results from all three 
studies.
The development of the RuSH system built many new partnerships and coalitions. State 
health department employees, health-care providers, academic institutions, community 
organizations, patients, and families were all important contributors to the program, and they 
worked closely with each other throughout the entire process. The combined efforts of these 
partners produced information that will allow for a better understanding of the impact of 
hemoglobinopathies on affected individuals identified in the participating states. This 
approach differs from many of the analyses that are currently available, which often use only 
a single data source.8–10 Our system showed that not all individuals were found in every 
data source and that the various sources contained different types of information. Therefore, 
we expect that the knowledge gained from combining all of these data will be more 
comprehensive than using a single data source on its own.
Furthermore, although the original intent of RuSH was to devise a standardized data 
collection protocol for all states to follow, it was quickly discovered that the same methods 
could not be used by all states because of the varying availability of both data sets and the 
identifying information contained within those data sets. Consequently, each state created a 
unique system for obtaining RuSH data, and the benefits and problems with each of these 
approaches can be compared and evaluated.
There were also limitations of the RuSH study design. The legal hurdles that were 
encountered when trying to obtain data-sharing agreements or memorandums of 
understanding to access data sets were time consuming and required the help of many 
people external to the program, including attorneys in some states. Most states found that the 
RuSH methods were suited to collecting data on people with SCD but did not work for 
people with thalassemia, presumably because of a lack of NBS data and nonspecific 
thalassemia-related ICD-9-CM codes during the years covered by this program. The 
individuals with a hemoglobinopathy diagnosis included in the study were limited to only 
those who were identified with the RuSH case definitions in at least one of the available data 
sources. Individuals who were not born in the state or who were born before universal 
screening was initiated, those not insured by Medicaid, or those who were not hospitalized 
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during the study period or provided care through an emergency department may not have 
been accounted for by the case-finding methods. Furthermore, because California was the 
only participating state that comprehensively screened all newborns for α- and β-
thalassemia, its genotype data for that condition was the most robust.
It is probable that the demographics of the individuals identified in RuSH may have been a 
result of the original data source(s) in which the person was found. For example, the lower 
mean age of the individuals identified as level 1 relative to that of individuals in the other 
levels is likely a reflection of the large portion of patients who were identified in NBS 
records as compared with clinical records. In addition, the use of Medicaid as a data source 
for some states may have resulted in a bias toward identification of individuals who were 
more likely to be younger (49% of Medicaid enrollees are younger than age 18) and female 
(58% of Medicaid enrollees) (http://kff.org/medicaid). One possible reason may be that 
although the optional criteria for extended Medicaid eligibility differ from state to state and 
year to year, the minimum core eligibility requirements include all children up to age 18 
with family incomes less than 100% of the Federal Poverty Level and pregnant women with 
family incomes up to 185% of the Federal Poverty Level (http://www.medicaid.gov).
Unfortunately, there was not an opportunity to evaluate or validate any of these components 
during the short project period. Consequently, a new project, the Public Health Research 
Epidemiology and Surveillance for Hemoglobinopathies (PHRESH), was implemented in 
two of the RuSH states (California and Georgia) to validate the data collection methods used 
in RuSH. PHRESH will result in a refined case definition and better understanding of the 
RuSH results, which will help to validate the information gathered during the pilot period. 
The states that are participating in PHRESH will use multiple methods to accomplish these 
activities, including review of medical records and establishment of new partnerships with 
additional clinical facilities. The goal is for these new clinical partnerships to help the 
surveillance system to both (i) identify individuals missed during the original RuSH data 
collection and (ii) provide additional information that can help strengthen the validity of the 
current case definitions.
The health-care utilization and clinical data collected in the RuSH system could serve as the 
foundation for the development of a patient registry that can be used to collect ongoing 
longitudinal information. A hemoglobinopathy registry that includes individuals who are 
identified through a population-based surveillance system will enable researchers to better 
understand the entire spectrum of the patient population—those who receive comprehensive 
care, those who use the emergency department as their main source of health care, those 
who have public/ private/no insurance, and those who have a mild presentation of the 
disease, among others. A system of this sort will allow researchers to answer specific 
questions that are important for the hemoglobinopathy community, such as the utilization of 
evidence-based care by the physicians who treat those with hemoglobinopathies. The 
knowledge gained from a registry will result in a better understanding of the conditions and, 
ultimately, improvement of the lives of the individuals with a hemoglobinopathy.
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Table 1
Case definitions for SCD and thalassemia
SCD Thalassemia
Level 1
• CLIA-certified laboratory result of SCD
a
 reported by a state 
newborn screening program with confirmatory testing, OR
• Clinical diagnosis
a
 by a physician with documented 
confirmatory CLIA-certified laboratory testing after the newborn 
period
• CLIA-certified laboratory result of DNA mutation 
analysis for thalassemia
e
 reported by a state newborn 
screening program with confirmatory testing OR
• Clinical diagnosis
e
 by a physician with documented 
confirmatory CLIA-certified laboratory testing by DNA 
mutation analysis after the newborn period
Level 2
• CLIA-certified laboratory result of SCD
a
 reported by a state 
newborn screening program without report of confirmatory 
testing, OR
• SCD ICD code at two or more separate health-care encounters 







• CLIA-certified laboratory result of thalassemia
e
 reported 




 by a physician with documented 
confirmatory CLIA-certified laboratory testing but 
without DNA mutation analysis after the newborn period 
OR
• Thalassemia ICD code at two or more separate health-







Level 3 • Sickle cell trait ICD code at two or more separate health-care 







• SCD ICD code for a single health-care encounter
• CLIA-certified laboratory result of thalassemia reported 
by results of state newborn screening program without 
report of confirmatory testing OR
• Thalassemia ICD code for a single health-care encounter
ICD-9-CM • 282.41 Sickle-cell thalassemia without crisis
• 282.42 Sickle-cell thalassemia with crisis
• 282.6 Sickle-cell disease, unspecified
• 282.61 Hemoglobin-SS disease without crisis
• 282.62 Hemoglobin-SS disease with crisis
• 282.63 Sickle-cell/hemoglobin-C disease without crisis
• 282.64 Sickle-cell/hemoglobin-C disease with crisis
• 282.68 Other sickle-cell disease without crisis
• 282.69 Other sickle-cell disease with crisis
• 282.5 Sickle-cell trait
• 282.4 Thalassemias
• 282.49 Other thalassemia
• 282.7 Other hemoglobinopathies
ICD-10-CM • D57 Sickle-cell disorders
• D57.0 Sickle-cell anemia with crisis
• D57.1 Sickle-cell anemia without crisis
• D57.2 Double heterozygous sickling disorders (hemoglobin S/C, 
hemoglobin S/D, hemoglobin S/E, sickle-cell thalassemia)
• D57.8 Other sickle-cell disorders





• D56.8 Other thalassemias
• D56.9 Thalassemia, unspecified
CLIA, Clinical Laboratory Improvement Amendments; ICD-CM, International Classification of Diseases Clinical Modification; SCD, sickle cell 
disease.
a
Includes hemoglobin S/S, hemoglobin S/β0 thalassemia, hemoglobin S/C, hemoglobin S/β+ thalassemia, and other compound heterozygous forms 
of SCD.
b
Chronic renal failure, proteinuria, pneumonia, acute chest syndrome, pulmonary hypertension, stroke (ischemic or hemorrhagic), transient 
ischemic attack, seizures, intracranial bleeding, priapism, iron overload, gallstones, cholelithiasis, cholecystitis, avascular necrosis, retinal disease, 
splenomegaly, splenic sequestration, hypersplenism, leg ulcers, dactylitis, and osteomyelitis.
c
Hydroxyurea, parenteral analgesics, iron chelators, erythropoietin, and folic acid.
d
Red cell transfusion, red cell exchange, splenectomy, cholecystectomy, and transcranial Doppler.
e
Includes hemoglobin H disease, hemoglobin H/Constant Spring, α-thalassemia major, β-thalassemia intermedia, β-thalassemia major, hemoglobin 
E/β0 thalassemia.
f
Pulmonary hypertension, iron overload, gallstones, cholelithiasis, cholecystitis, splenomegaly, splenic sequestration, or hypersplenism.
g
Iron chelators.
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h
Red-cell transfusion, splenectomy, cholecystectomy.
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Table 2
Number of individuals with a sickle cell disease diagnosis by state and case definition level, 2004-2008
State Level 1 Level 2 Level 3
California 1,976 3,159 8,724
Florida 443 6,909 23,916
Georgia 4,288 2,721 8,918
Michigan 1,504 967 8,818
New York 1,049 6,655 14,863
North Carolina 4,404 1,141 1,708
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Table 3
Number of individuals with a thalassemia diagnosis by state and case definition level, 2004-2008
State Level 1 Level 2 Level 3
California 836 1,915 14,534
Florida 14 1,620 6,731
Georgia 64 271 4,553
Michigan 6 31 1,354
New York 33 1,873 10,380
North Carolina 84 232 1,127
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Table 4
Genotypes of level 1 individuals by state, 2004-2008
California Florida Georgia Michigan New York North Carolina
Sickle cell disease
    Total
h 1,976 443 4,288 1,504 1,049 4,404
    Sickle cell anemia (hemoglobin S/S) or 
hemoglobin S/β0 thalassemia
1,178 (59.6) 288 (65.0) 2,840 (66.2) 831 (55.3) 635 (60.5) 2,588 (58.8)
    Sickle C disease (hemoglobin S/C) 489 (24.7) 126 (28.4) 1,111 (25.9) 501 (33.3) 364 (34.7) 1,265 (28.7)
    Hemoglobin S/β+ thalassemia 183 (9.3) 25 (5.6) 309 (7.2) 168 (11.2) 41 (3.9) 431 (9.8)
    Other compound heterozygous forms of sickle 
cell disease
75 (3.8) 4(0.9) 28 (0.7) 4(0.3) 9(0.9) 120 (2.7)
Thalassemia
    Total
b 836 14 64 6 33 84
    Hemoglobin H disease 507 (60.6) 1 (7.1) 8 (12.5) 0 (0) 0 (0) 5 (6.0)
    Hemoglobin H/Constant Spring 64 (7.7) 0 (0.0) 5 (7.8) 0 (0) 0 (0) 0 (0)
    α-Thalassemia major 9 (1.1) 4 (28.6) 0 (0) 0 (0) 0 (0) 0 (0)
    α-Thalassemia, other 4 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2.4)
    β-Thalassemia intermedia 18 (2.2) 3 (21.4) 7 (10.9) 0 (0) 7 (21.2) 9 (10.7)
    β-Thalassemia major 127 (15.2) 2 (14.3) 31 (48.4) 0 (0) 0 (0) 19 (22.6)
    Hemoglobin E/β0 thalassemia 62 (7.4) 2 (14.3) 9 (14.1) 6 (100) 0 (0) 5 (6.0)
    β-Thalassemia, other 44 (5.3) 2 (14.3) 4 (6.3) 0 (0) 26 (78.8) 44 (52.4)
Data are n (%).
a
Of patients with sickle cell disease In California, 2.6% had an unknown genotype.
b
Of patients with thalassemia In California, 0.1% had an unknown genotype.
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